Harry Sarles, MD
Gastroenterology · Rockwall, TXNPI 1861451395
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,648 of the $70,616 with a category attached, or 60.4%. Phathom Pharmaceuticals, Inc. accounts for 66.7% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2024 at $46,210 and has fallen 85.7% since, to $6,595 in 2025. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 692 payments — averaging $102.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$47K
- AbbVie$6K
- Johnson & Johnson$3K
- Regeneron Healthcare Solutions, Inc.$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $7K from 36 others
Across 735 payments — averaging $5487.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.4M
- Regeneron$452K
- Janssen Research & Development, LLC$421K
- E.r. Squibb & Sons, L.L.C.$417K
- Takeda Pharmaceuticals U.S.A., Inc.$270K
- Gilead$264K
- plus $805K from 13 others
What the payments were for
- Consulting fees$9,01813%
- Speaking & faculty fees$42,64860%
- Travel & lodging$4,4576%
- Food & beverage$14,46520%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,616 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntyvioVedolizumab | 13 | $110,882 |
| LinzessLinaclotide | 23 | $23,112 |
| Mesalamine | 17 | $7,657 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 30 | $4,730 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 204 | $4,447 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 12 | $1,981 |
| Dicyclomine Hcl | 61 | $1,978 |
| Ursodiol | 15 | $1,972 |
| Colestipol Hcl | 12 | $1,805 |
| Pantoprazole Sodium | 117 | $1,736 |
| Omeprazole | 107 | $1,649 |
| Amitriptyline Hcl | 19 | $669 |
| Ondansetron OdtOndansetron | 11 | $253 |
| Famotidine | 14 | $244 |
| Metoclopramide Hcl | 14 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $1,286 | $110,88213 claims |
| AbbVieLinzess | $5,583 | $23,11223 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $272 | $4,73030 claims |
| Braintree Laboratories, Inc.Sutab | $34 | $1,98112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Rockwall
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
- Nadege GunnWaco$933K
- Brooks CashHouston$867K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.